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Depressive disorders have a great impact on well-being and daily 
functioning and are a major health problem with a 12-month 
prevalence rate between 6.3 and 10.3% across Western societies.1,2 
Diverging treatment results, partly ascribed to the non-specificity 
of major depression, have led to proposals for depressive subtyping 
models based on characteristics like observed symptom profiles, 
aetiology, time of onset, gender, duration of complaints and treat-
ment response.2 Ideally, subtypes should represent homogeneous 
groups of cases and represent different underlying pathophysiolog-
ical processes that allow us to develop specific treatment strategies.
Seasonal affective disorder (SAD) is one of the proposed sub-
types of depression with a specific treatment strategy.3 SAD is a syn-
drome originally defined to describe recurrent depressive episodes 
with a characteristic temporal pattern. The depressive episodes usu-
ally occur in autumn and winter and remit the following spring or 
summer. In the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV and DSM-5), seasonality is added as one of the specifiers of 
bipolar or recurrent major depressive disorders (MDDs). According 
to this specifier, seasonal episodes should substantially outnumber 
non-seasonal episodes. Subsyndromal SAD (sub-SAD) is a milder 
form of SAD describing complaints in wintertime in participants 
who fail to meet the number of complaints required for a DSM 
diagnosis of depression. Sub-SAD can be considered to be part of 
a continuum of seasonality between no complaints at all and clini-
cally depressed. Disturbance of circadian rhythm because of lack of 
daytime light in the winter months is thought to play a role in the 
aetiology of SAD. Light therapy is an efficacious and well- tolerated 
treatment for SAD with effect sizes equivalent to those of most anti-
depressants and has been adopted as the treatment of choice for SAD 
in treatment guidelines for depression.3,4
Yet, there still remains a debate as to whether SAD is a distinct 
depressive subtype or a pronounced seasonality trait of patients 
with fluctuating minor and major depression.5 Several researchers 
have questioned the validity of the concept of SAD. For example, 
Traffanstedt et al who could not find a relation between depres-
sion and season in a large population-based study, and Hansen 
who argued that disturbance in circadian rhythm seems to be more 
related to midwinter insomnia and tiredness during the day than to 
depressed mood.6–8 On the contrary, researchers stress the impor-
tance of longitudinal research and the low prevalence of SAD in 
population-based studies.9
In the Netherlands, Mersch et al10 studied the prevalence and 
characteristics of SAD and sub-SAD in the general population. 
In that study Mersch et al used the Seasonal Pattern Assessment 
Questionnaire (SPAQ), which is a commonly used screening 
instrument for SAD.11–13 SAD and sub-SAD criteria were met 
by  3.1 and 8.5% of the respondents, respectively. However, 
no data are available yet on the prevalence of SAD in the 
Netherlands in large patient populations with depressive and anx-
iety disorders.
In a meta-review of depressive subtyping models, Baumeister 
argued that the main obstacle to research on SAD as a distinct sub-
type of depression is the lack of studies comparing patients with 
and without SAD in terms of a specific clinical picture, bio-psycho-
social correlates and specific treatment responsiveness.2
Aims
In answer to the call for comparative studies within patient pop-
ulations, we aimed to compare the clinical, demographic and 
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Background
Seasonal affective disorder (SAD) is considered to be a 
subtype of depression.
Aims
To compare the clinical picture of SAD to non-seasonal 
affective disorders (non-SADs).
Method
Diagnoses according to the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV) were established in 2185 
participants of the Netherlands Study of Depression and 
Anxiety. The Seasonal Pattern Assessment Questionnaire 
was administered to diagnose SAD. Symptoms of depression 
and anxiety were measured with the Inventory of Depressive 
Symptoms, the Beck Anxiety Inventory and the Fear 
Questionnaire.
Results
Participants with SAD, participants with a lifetime bipolar 
disorder and participants with a lifetime comorbid anxiety 
and depressive disorder scored highest in terms of 
psychopathology in the past year. The seasonal distribution of 
major depressive episodes was not different for participants 
with or without SAD.
Conclusions
SAD may be a measure of severity of depression with a 
subjectively perceived worsening of symptoms in the winter 
months.
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personality characteristics of persons with SAD with those of per-
sons with non-seasonal affective disorders (non-SADs) and healthy 
 controls (HC).
Therefore, we first assessed the prevalence of SAD and sub
-SAD in a well-described population with affective disorders and 
HC and recorded to what diagnostic groups they belonged. Second, 
we compared the clinical characteristics of participants with SAD 
and sub-SAD with those of participants with lifetime non-SADs, 
including bipolar disorders (BPDs), and HC. Third, we zoomed in 
on participants with SAD and participants with a lifetime depres-
sive disorder or a lifetime comorbid anxiety and depressive dis-
order (ADD). We compared their clinical characteristics and the 
seasonal distribution of the scores on a depression questionnaire 
and two anxiety questionnaires. Finally, we compared the seasonal 
distribution of depressive episodes (current MDD) in participants 
with and without SAD.
Method
The study was conducted using data from the Netherlands Study 
of Depression and Anxiety (NESDA) (http://www.nesda.nl).1 
NESDA is an ongoing multisite naturalistic longitudinal cohort 
study among 2981 adults (18–65 years), aimed at describing the 
long-term course and consequences of depressive and anxiety 
disorders. The NESDA sample is stratified by setting community, 
primary care and specialised mental healthcare. Across recruit-
ment settings, uniform inclusion and exclusion criteria were 
used. The NESDA sample included participants with a range of 
psychopathology: those with no lifetime anxiety or depressive 
disorders (HC), and those with a current first or recurrent depres-
sive disorder (MDD or dysthymic disorder) or anxiety disorder 
(panic disorder with or without agoraphobia, agoraphobia, social 
phobia or generalised anxiety disorder). Patients with a clinically 
overt psychotic disorder, BPD, obsessive–compulsive disorder, or 
severe substance use disorder, and persons not fluent in Dutch 
were excluded from the baseline assessment.
In this study, the identification of participants suffering from 
SAD and sub-SAD was based on the SPAQ, which was admin-
istered at the 1-year follow-up measurement. The diagnoses 
according to the criteria of the Diagnostic and Statistical Manual 
of Mental Disorders (DSM-IV) and the symptom and personality 
questionnaires were established one year later in the 2-year face-
to-face follow-up interview. Measurements for this study started in 
September 2005 and lasted until February 2008.
Measures
The identification of participants suffering from SAD and sub-SAD 
was based on the SPAQ. The SPAQ is a self-rating screening instru-
ment for SAD that retrospectively measures variation in mood and 
behaviour by month.11 The psychometric properties of the SPAQ 
are acceptable with test–retest reliability varying from 0.58 to 0.87, 
internal consistency varying from 0.74 to 0.82, specificity varying 
from 73 to 94% and sensitivity varying from 31.8 to 94% in differ-
ent studies.13–16
The criteria for SAD and sub-SAD for the SPAQ have been 
 formulated by Kasper et al.12 The SPAQ applies the following three 
criteria that have to be met to reach the diagnosis of SAD:
(1) The Global Seasonality Scale (GSS) provides a composite 
measure for change in mood, social activities, appetite, 
sleep, weight and energy across the seasons. Scales range 
from (0) ‘no change’ to (4) ‘extremely marked change’. 
The total score ranges from 0 to 24. We used the Kasper 
introduced and most widely used cut-off score of 11 for the 
self-report version of the SPAQ.12
(2) A second criterion for SAD is based on the question 
whether seasonal changes are considered a problem. The 
response possibilities range from 0=no problem to 5=a dis-
abling problem. A score of at least 2 (a moderate problem) 
is necessary to reach the SAD threshold.
(3) Finally, the timing of the seasonal problems (summer or 
winter) is determined by asking in which months partici-
pants feel worst (the ‘window’).
In this study, we defined the window for SAD (winter type) pos-
itive if participants reported that they usually feel worst in the win-
ter months (December and/or January and/or February) and not in 
the summer months (June and /or July and/or August). Sub-SAD 
is defined as a cluster of seasonal complaints that are not severe 
enough to allow for a diagnosis of SAD. The criteria for sub-SAD 
are a GSS of 9 or 10 for the self-report version of the SPAQ, regard-
less of whether the participant considers the seasonal changes to be 
a problem or not, or a GSS of at least 11 and ‘no’ or ‘mild’ problems 
with the seasonal changes.12 The window is the same as for SAD.
In the 2-year follow-up interview, the Composite International 
Diagnostic Interview (CIDI) (WHO version 2.1) was used to estab-
lish current (last month) and lifetime diagnoses of depressive and 
anxiety disorders according to DSM-IV criteria.
The CIDI is used worldwide, and WHO field research has found 
high interrater reliability, high test–retest reliability and high valid-
ity for depressive and anxiety disorders.1 The bipolar section of the 
CIDI was included in this interview to identify participants with 
a lifetime BPD. The dates of the 2-year follow-up interview were 
recorded and were categorised into the four seasons (spring: March 
21–June 20, summer: June 21–September 20, autumn: September 
21–December 20 and winter: December 21–March 20).
Clinical characteristics of the participants were assessed 
together with the CIDI using the following instruments:
(1) The Inventory of Depressive Symptoms, 30-item self-report 
version (IDS), was used to assess the severity of depres-
sion.1 The IDS was also used to specify atypical and melan-
cholic features of depressive symptoms based on DSM-IV 
criteria. For atypical features, the algorithm of Novick 
et al17 was used, identifying participants with mood reac-
tivity and two or more of the following symptoms: hyper-
phagia, hypersomnia, leaden paralysis and interpersonal 
rejection sensitivity. In NESDA, a small adaptation for the 
interpersonal rejection sensitivity item threshold value was 
used. For the melancholic subtype, the algorithm of Khan 
et al was used to identify participants lacking mood reac-
tivity and loss of pleasure in (almost) all activities. They 
also had to report more than three of the following symp-
toms: distinct quality of depressed mood, mood is worse 
in the morning, early morning awakening of at least 1 h 
before usual time, psychomotor retardation or agitation, 
significant anorexia or weight loss, and excessive or inap-
propriate guilt.18 These two variables, atypical and melan-
cholic features, were calculated regardless of the presence 
of a current MDD diagnosis.
(2) The Beck Anxiety Inventory (BAI), a 21-item self-report 
instrument, was used to assess overall severity of anxiety.1 
The 15-item self-report version of the Fear Questionnaire 
(FQ) was used to measure severity of fear and avoidance.1
(3) The 60-item NEO Five-Factor Inventory was used to mea-
sure five personality domains: neuroticism, extraversion, 
agreeableness, conscientiousness and openness to experi-
ence.1 Current antidepressant, anxiolytic and antipsychotic 
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medication use was registered, based on drug-container 
inspection of all the drugs used in the past month (on at 
least 50% of days), and classified according to the World 
Health Organization Anatomical Therapeutic Chemical 
classification.1
Percentage of time with depressive, anxiety and avoidance 
symptoms during the past 2 years was assessed with the Life Chart 
interview that uses a calendar approach to measure duration of 
symptoms.1
Participants
In our first analysis, we used the SPAQ, assessed at the 1-year fol-
low-up measurement, to establish the frequency of SAD and sub- 
SAD and we recorded to what diagnostic groups as assessed in the 
2-year follow-up CIDI interview the participants belonged.
We defined a group of participants with a current (1 month) 
MDD. Next, we defined five mutually exclusive groups according 
to the DSM-IV lifetime diagnoses: (1) depressive disorder, that is, 
MDD and/or dysthymic disorder (D); (2) anxiety disorder (A); 
(3) comorbid anxiety and depressive disorder (AD); (4) BPD; and 
(5) HC.
In our second analysis, we compared participants with SAD and 
sub-SAD with participants with lifetime non-SADs. For this goal, 
participants were exclusively assigned to one of the seven groups: 
(1) SAD; (2) sub-SAD; (3) BPD and no (sub-)SAD (BPD-NS); 
(4) depressive disorder, that is, MDD and/or dysthymic disorder, 
and no (sub-)SAD (D-NS); (5) anxiety disorder and no (sub-)SAD 
(A-NS); (6) comorbid ADD, no (sub-)SAD (AD-NS); and (7) HC 
and no (sub-) SAD (HC-NS).
In our third analysis, demographic and clinical characteristics 
of participants with SAD were compared with those of participants 
with a lifetime depressive disorder or a lifetime comorbid ADD, 
and no (sub)-SAD (ADD-NS).
In our fourth analysis, we compared the seasonal distribution 
of the scores on the IDS, BAI and FQ of participants with SAD to 
ADD-NS.
In our fifth analysis, participants with a current MDD and SAD 
(MDD-S) were compared to participants with a current MDD and 
no (sub-)SAD (MDD-NS).
Statistical analysis
Pairwise comparisons were conducted for SAD versus non-SAD. 
Groups were compared using t-tests for continuous variables and 
chi-square tests for discrete variables.
Logistic regression analyses with age and gender as covari-
ates were used to determine which demographic variables (North 
European descent, married, divorced, years of education, employ-
ment status, income <€800, income <€1400), which psychopatho-
logical variables were present last year and last month (MDD, 
dysthymia, social phobia, panic disorder with agoraphobia, panic 
disorder without agoraphobia, agoraphobia, generalised anxiety 
disorder) and which clinical variables (mean IDS, atypical and 
melancholic features of IDS, BAI, FQ, use of antipsychotic drugs, 
use of anxiolytic drugs, use of antidepressant drugs, neuroticism, 
extraversion, openness, agreeableness and conscientiousness, 
percent of time with symptoms of depression, anxiety or both 
depression and anxiety) significantly predicted the presence of 
SAD versus ADD-NS. These variables were subsequently entered 
together in a multivariate logistic regression analysis. Variables 
that did not predict the presence of SAD were removed one by 
one. A threshold of 0.05 was used in order to minimise the risk 
of type 1 errors.
Analysis of variance (ANOVA) was used to test whether there 
was a difference in IDS scores (2-year follow-up assessment) across 
seasons in the SAD group versus the ADD-NS group. Season 
(spring, summer, autumn, winter), group (SAD and ADD-NS) and 
the interaction between season and group were used as predictors 
in this model.
In logistic regression analyses with age and gender as covari-
ates, we used the same variables as described in the comparison of 
SAD and AD-NS to determine which variables significantly pre-
dicted the presence of MDD-S versus MDD-NS. ANOVA was used 
to test whether there was a difference in IDS scores across seasons 
in the MDD-S group versus the MDD-NS group. Finally, a chi-
square test was used to test whether there was a difference in fre-
quency distribution of MDD-S and MDD-NS across the seasons.
Analyses were conducted using SPSS version 22 statistical soft-
ware (SPSS Inc., Chicago, Illinois). A two-sided P-value of 0.05 
was used as the significance level with no correction for multiple 
comparison.
Ethics statement
The study protocol of NESDA was approved by the Ethical Review 
Boards of the VU University Medical Center, the Leiden University 
Medical Center and the University Medical Center Groningen. 
After full verbal and written information about the study, written 
informed consent was obtained from all participants at the start of 
baseline assessment. A full ethics statement of NESDA and detailed 
information on objectives and methods of NESDA were published 
elsewhere.1
Results
Of the original 2981 participants in the NESDA study, 536 (18%) 
participants did not return the 1-year follow-up questionnaire 
containing the SPAQ questionnaire and 99 participants had miss-
ing scores on the SPAQ. These participants were excluded from 
the analysis. Of the remaining 2346 participants, 161 participants 
(5.4%) did not participate in the interview at the 2-year follow-up, 
resulting in 2185 participants included in this analyses. In this sam-
ple, the proportion of women (67.5%) did not significantly deviate 
from the proportion of women (66.4%) in the overall sample of 
NESDA. Of the 2185 participants, 356 were diagnosed with D, 241 
were diagnosed with A, 1021 with AD and 91 with BPD (Table 1). 
Four hundred and seventy-six participants (HC) did not have a 
lifetime CIDI diagnosis of a depressive, anxiety or BPD. Of the 
2185 participants 283 were diagnosed with MDD.
Distribution of SAD across CIDI diagnoses
According to the Kasper criteria, 100 (4.6%) of the 2185 partici-
pants suffered from SAD. For men and women, the percentages 
were 3.8 and 4.9%, respectively. Sub-SAD according to the Kasper 
criteria was present for 149 (6.8%) participants: 43 (6.1%) men and 
106 (7.2%) women.
Table 1 shows to which diagnostic groups SAD and sub-SAD 
participants belonged according to the CIDI interview. Highest 
percentages were seen in the BPD and AD groups, intermediate 
percentages for D and A groups, and lowest percentages for the HC 
group. Of the 1377 participants with a lifetime depressive disorder 
or a lifetime comorbid ADD, 6.0% fulfilled the SPAQ criteria of 
SAD and 8.1% fulfilled the SPAQ criteria of sub-SAD.
Of the 283 participants with an MDD, 36 (12.7%) fulfilled 
the SPAQ criteria of SAD and 32 (11.3%) fulfilled the criteria of 
sub-SAD.
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was significantly higher than the mean score of the ADD-NS 
group: F(1, 1266)=21.51, P<0.01. Also for the scores on the BAI 
and the FQ, there were no significant seasonal differences between 
the groups (data not shown).
Current MDD with SAD compared with current 
MDD without SAD
The MDD-S group consisted of 36 participants. The MDD-NS 
group consisted of 215 participants. Table 4 shows the seasonal dis-
tribution of MDD-S and MDD-NS. A chi-square test showed that 
there was no statistical significant difference in seasonal distribu-
tion between MDD-S and MDD-NS: χ2 (3)=5.876, P=0.118.
In the logistic regression analyses and subsequent multivariate 
logistic regression analysis, only the melancholic features signifi-
cantly predicted the presence of MDD-S versus MDD-NS, with an 
odds ratio of 2.39 (95% CI 1.00–5.70), P=0.049.
ANOVA showed that there were no statistically significant sea-
sonal differences in IDS scores for MDD-S versus MDD-NS: F(3, 
246)=0.21, P=0.89. After removal of the interaction term, ANOVA 
showed that there was no significant overall effect for the seasons: 
F(3, 246)=1.34, P=0.26. In this last model, there was also no signifi-
cant difference in mean IDS score between MDD-S and MDD-NS: 
F(3.246)=0.17, P=0.68.
Also for the scores on the BAI and the FQ, there were no 
significant seasonal differences between the groups (data not 
shown).
Discussion
In this large naturalistic study among participants with affective 
disorders and HC, the overall prevalence of SAD and sub-SAD 
was comparable to the prevalence in the general population in the 
Netherlands: 4.6% for SAD versus 3.1% in the general population 
and 6.8% for sub-SAD versus 8.5% in the general population.10
The prevalence of SAD was low within the bipolar group 
(12.1%) and anxiety disorder group (1.7%) when compared with 
studies that also used the SPAQ in a clinical population (BPD 27.3%, 
panic disorder 30.1%).19–21 For the bipolar group, an explanation for 
the low prevalence of SAD might be that the bipolar group in this 
study was not a fully representative sample of patients with a BPD, 
because our bipolar group consisted of participants with no clinical 
history of BPD at baseline measurement who were diagnosed at 
the 2-year follow-up measurement with the CIDI.22 For the anxi-
ety disorder group, an explanation might be that Marriot studied 
exclusively patients with a panic disorder and used a cut-off score 
of 10 on the GSS for SAD.20
The prevalence of SAD within the group of participants suffer-
ing from current MDD (12.7%) was comparable to the finding of 
Levitt et al23 (11%) in a Canadian community sample.23
In our study, participants suffering from SAD presented a 
severe clinical picture. Like participants with a lifetime BPD and 
SAD compared with non-SADs (lifetime diagnoses) 
and HC: demographic and clinical characteristics
Table 2 shows the demographic and clinical characteristics of the 
2185 participants in seven diagnostic groups.
The proportion of men was higher in the BPD-NS and HC-NS 
group compared to SAD. Compared to SAD, participants in the sub
-SAD group were younger. Participants in the SAD group were less 
frequently employed than participants in the other groups (except 
for BPD-NS) but the difference was not significant for AD-NS and 
BPD-NS. Like BPD-NS, participants with SAD were most likely to 
have an income below €1400 per month.
Participants in the SAD, BPD-NS and AD-NS groups scored 
highest in terms of psychopathology in the last month and in terms 
of psychopathology in the past year. At the 2-year follow-up, partic-
ipants in the SAD group scored higher than the other groups on the 
IDS, BAI and FQ but there was no significant difference between 
SAD and BPD-NS.
SAD compared with lifetime depressive disorders: 
demographic and clinical characteristics
The SAD group consisted of 100 participants. The ADD-NS group 
consisted of 1183 participants diagnosed with a lifetime depressive 
disorder or a lifetime comorbid ADD, and no SAD or sub-SAD.
The logistic regression analyses showed that the following 
variables predicted the presence of SAD: age, employment status, 
income category below €1400 per month, neuroticism, MDD last 
year, agoraphobia last year, generalised anxiety disorder last year, 
mean IDS scores (2-year follow-up assessment), melancholic fea-
tures of the IDS, FQ mean score, BAI anxiety mean score and use 
of antipsychotics.
In the successive multivariate logistic regression analysis, we 
did not include the BAI because the IDS and the BAI showed a 
high correlation of 0.80. We also did not include 1-month diagno-
ses because of the overlap between 2-year and 1-month diagnoses.
In the last model, after removing the variables that were not 
significant, the variables age, income below €1400, MDD last year, 
agoraphobia and high melancholic features on the IDS significantly 
predicted the presence of SAD versus ADD-NS (Table 3).
SAD compared with lifetime depressive disorders: 
seasonality of depressive and anxiety symptoms
Figure 1 shows the scores on the IDS (2-year follow-up assessment) 
in the four seasons for SAD and ADD-NS. The figure suggests that 
IDS scores in autumn and winter were higher than in spring and 
summer for the SAD group. However, ANOVA showed that there 
was no significant interaction between the seasons and the groups: 
F(3, 1266)=0.82, P=0.48, meaning that the seasonal differences 
in IDS scores were not different for SAD versus ADD-NS. After 
removal of the interaction term, ANOVA showed that there was 
also no significant overall effect for the seasons: F(3, 1266)=1.84, 
P=0.14. In this last model, the mean IDS score of the SAD group 














SADa 14 (3.9%) 4 (1.7%) 69 (6.8%) 11 (12.1%) 2 (0.4%) 100 (4.6%)
sub-SADa 21 (5.9%) 16 (6.6%) 90 (8.8%) 11 (12.1%) 11 (2.3%) 149 (6.8%)
SAD, seasonal affective disorder; sub-SAD, subsyndromal seasonal affective disorder a. Kasper criteria applied to the SPAQ. b. Diagnostic categories assessed with the CIDI: D, any 




















  Age at baseline (years), 
mean (s.d.)
42.9 (11.7) 43.6 (13.0) 43.4 (13.5) 43.5 (12.3) 42.5 (14.4) 41.0 (12.7) 36.8 
(11.8)**
42.7 (13.1)
 Female, n (%) 38 (55.1%)* 207 (64.5%) 143 (64.7%) 619 (71.8%) 289 
(62.4%)*
73 (73.0%) 106 (71.1%) 1475 
(67.5%)
  North European 
descent, n (%)
67 (97.1) 309 (96.3%) 211 (95.5%) 825 (95.7%) 450 
(97.2%)*
92 (92.0%) 142 (95.3%) 2096 
(95.9%)
 Married (%) 32 (46.4%) 131 (40.8%) 106 
(48.0%)*
347 (40.3%) 221 
(47.7%)*
34 (34.0%) 44 (29.5%) 915 (41.9%)
 Divorced (%) 9 (13.0%) 59 (18.4%) 22 (10.0%)* 147 (17.1%) 37 (8.0%)** 18 (18.0%) 23 (15.4%) 315 (14.4%)
  Years of education, 
mean (s.d.)
12.0 (3.6) 13.0 (3.3) 12.9 (3.3) 12.2 (3.3) 13.2 (3.3) 12.6 (3.0) 12.4 (3.0) 12.6 (3.3)




510 (60.6%) 312 
(69.6%)*




  Income <€ 800 per 
month, n (%)b
7 (10.1%) 12 (3.8%) 6 (2.7%) 37 (4.3%) 29 (6.3%) 5 (5.2%) 7 (4.8%) 103 (4.8%)
  Income <€ 1400 per 
month, n (%)b
21 (30.4%) 55 
(17.2%)**




34 (35.1%) 31 (21.1%)* 434 (20.1%)
Psychopathology last year (2-year follow-up measurement – CIDI) 
  Major depressive 
disorder, n (%)




– 57 (57.0%) 64 (43.0%)* 564 (25.8%)
 Dysthymia, n (%) 22 (31.9%)* 14 (4.4%)** – 139 (16.1%) – 18 (18.0%) 15 (10.1%) 208 (9.5%)
 Social Phobia, n (%) 17 (24.6%) – 32 (14.5%) 203 (23.5%) – 23 (23.0%) 36 (24.2%) 311 (14.2%)
  Panic disorder with 
agoraphobia, n (%)
12 (17.4%)* – 11 (5.0%) 80 (9.3%) – 7 (7.0%) 10 (6.7%) 120 (5.5%)
  Panic disorder without 
agoraphobia, n (%)
12 (17.4%)* – 18 (8.1%) 92 (10.7%) – 6 (6.0%) 14 (9.4%) 142 (6.5%)
 Agoraphobia, n (%) 8 (11.6%) – 19 (8.6%) 86 (10.0%) – 14 (14.0%) 12 (8.1%) 139 (6.4%)
  Generalised anxiety 
disorder, n (%)
10 (14.5%) – 8 (3.6%)** 130 (15.1%) – 18 (18.0%) 13 (8.7%)* 179 (8.2%)
Psychopathology last month (2-year follow-up measurement – CIDI)
  Major depressive 
disorder, n (%)
23 (33.3%) 27 (8.4%)** – 165 
(19.1%)**
– 36 (36.0%) 32 (21.5%)* 283 (13.0%)
 Dysthymia, n (%) 18 (26.1%) 10 (3.1%)** – 110 (12.8%) – 17 (17%) 11 (7.4%)* 166 (7.6%)
 Social phobia, n (%) 16 (23.2%) – 26 (11.8%)* 160 (18.6%) – 21 (21.0%) 31 (20.8%) 254 (11.6%)
  Panic disorder with 
agoraphobia, n (%)
6 (8.7%) – 7 (3.2%) 61 (7.1%) – 6 (6.0%) 10 (6.7%) 90 (4.1%)
  Panic disorder without 
agoraphobia, n (%)
7 (10.1%) – 10 (4.5%) 58 (6.7%) – 3 (3.0%) 12 (7.4%) 89 (4.1%)
 Agoraphobia, n (%) 4 (5.8%) – 10 (4.5%)* 61 (7.1%) – 11 (11.0%) 11 (7.4%) 97 (4.4%)
  Generalised anxiety 
disorder, n (%)
7 (10.1%) – 7 (3.2%)** 93 (10.8%) – 14 (14.0%) 11 (7.4%) 132 (6.0%)
Symptoms of depression and anxiety (2-year follow-up measurement)
 IDS, mean (s.d.)c 26.8 (14.4) 12.7 (9.1)** 12.4 (8.2)** 20.0 (12.1)* 6.1 (5.2)** 24.0 (13.0) 19.5 (10.7)* 15.5 (11.9)
  IDS atypical featuresc 10 (14.7%) 9 (2.8%)** 4 (1.8%)** 71 (8.4%) 0 (0.0%)** 12 (12.4%) 10 (6.9%) 116 (5.4%)
  IDS melancholic 
featuresd
10 (14.7%) 2 (0.6%)** 2 (0.9%)** 25 (3.0%)* 0 (0.0%)** 9 (9.3%) 5 (3.5%) 53 (2.5%)
 BAI, mean (s.d.)c 16.1 (12.0) 5.7 (5.8)** 7.4 (7.4)** 11.2 (9.0)* 2.9 (3.7)** 14.0 (10.1) 11.1 (8.8)* 8.5 (8.6)




24.8 (18.6)* 9.0 (8.9)** 29.2 (20.0) 25.2 (19.4) 18.9 (17.2)
Medication use 
  Use of antipsychotic 
drug, n (%)
10 (14.5%) * 4 (1.2%)* 1 (0.5%)** 13 (1.5%)* 0 (0.0%)** 5 (5.0%) 1 (0.7%)* 34 (1.6%)
  Use of anxiolytica drug, 
n (%)
17 (24.6%)* 8 (2.5%)* 20 (9.0%) 96 (11.1%) 5 (1.1%)** 10 (10.0%) 16 (10.7%) 172 (7.9%)
  Use of antidepressant 
drug, n (%)




291 (33.8%) 5 (1.1%)** 36 (36.0%) 39 (26.2%) 479 (21.9%)
Global seasonality score, 
mean (s.d.)f
5. 5 (4.2)** 4.0 (2.9)** 3.2 (2.6)** 4.8 (3.2)** 2.6 (2.3)** 13.7 (2.7) 10.2 (1.7)** 4.9 (3.9)
BPD-NS, bipolar disorder (no SAD or sub-SAD); D-NS, any depressive disorder, lifetime diagnosis (no SAD or sub-SAD); A-NS, any anxiety disorder, lifetime diagnosis (no SAD or 
sub-SAD); AD-NS, any depressive disorder, lifetime diagnosis + any comorbid anxiety disorder, lifetime diagnosis (no SAD or sub-SAD); HC-NS, healthy control (no SAD or sub-SAD); 
SAD, seasonal affective disorder; sub-SAD, sub-seasonal affective disorder; IDS, Inventory of Depressive Symptoms; BAI, Beck Anxiety Inventory; FQ, Fear Questionnaire. Pairwise 
comparisons T-test for continuous variables Chi-square test for discrete variables a. n=2156 b. n=2154 c. n=2151 d. n=2128 e. n=2164 f. n=2185. Based on chi-square test for 
 categorical variables and ANOVA for continuous variables, *P<0.05 **P<0.01.
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Seasonality of symptoms, mainly a psychological 
phenomenon?
In this study, there was no significant difference between the sea-
sons in scores on psychopathological and clinical variables, nei-
ther for participants with any lifetime depressive disorder nor for 
participants with SAD. Also the seasonal distribution of a current 
MDD was not significantly different for participants with or with-
out SAD. Finally, there was no statistically significant difference in 
severity of depressive and anxiety symptoms between participants 
with a current MDD and SAD and participants with a current 
MDD and no SAD.
Although a number of studies showed that within clinical 
populations, patients with SAD experience variation in symptom 
severity over seasons,21,27 other studies had different findings.28,29 In 
a large cohort of bipolar patients, Murray et al30 could not find a 
significant seasonal pattern for depressive symptoms. Furthermore 
in a systematic review on seasonality and BPD, the association 
between symptoms and seasonality in BPD was found to be lim-
ited.31 Also in a large population of out-patient psychiatric patients, 
no seasonal fluctuation in severity of depressive symptoms could 
be demonstrated.32 Furthermore, there is some concern consider-
ing the stability of the diagnosis of SAD. For example, Sakamoto 
found that only 22% of the SAD patients consistently showed a 
participants with a lifetime comorbid ADD, the SAD group scored 
high in terms of psychopathology in the last month and in terms of 
psychopathology in the past year. In contrast to our findings, SAD 
has been described previously as a relatively mild variant of depres-
sion characterised by an atypical symptom profile and with lower 
occupational and cognitive impairment than non-seasonal depres-
sion.24,25 On the contrary, in other studies SAD was associated with 
high impairment and high comorbidity rates of BPD, phobias and 
somatoform disorders.5,15,26



















Table 3 SAD versus ADD-NS (lifetime)a
Unadjusted odds 
ratio Exp(B) 95% CI Sig.
Adjusted odds 
ratio Exp(B)b 95% CI Sig.
Lower Upper Lower Upper
Age at 2-year follow-up 0.984 0.968 1.000 0.047 0.983 0.966 1.000 0.052
Female 1.169 0.739 1.848 0.506 1.079 0.663 1.754 0.760
Income < €1400 per month 2.114 1.360 3.284 0.001 1.711 1.076 2.722 0.023
Major depressive disorder last year 2.655 1.755 4.016 <0.001 2.586 1.649 4.056 <0.001
Agoraphobia last year 2.077 1.133 3.806 0.018 1.995 1.039 3.831 0.038
IDS melancholic features 4.322 1.971 9.475 <0.001 2.732 1.195 6.245 0.017
IDS, Inventory of Depressive Symptoms; MDD, major depressive disorders; SAD, seasonal affective disorder. a. SAD, seasonal affective disorder according to SPAQ criteria (n=94); 
ADD-NS, a lifetime depressive disorder or a lifetime comorbid anxiety and depressive disorder and no SAD or sub-SAD (n=1160). b. Based on multivariate logistic regression analysis 
with age and gender as covariates.
Table 4 Seasonal distribution of current major depressive disorder in 
participants with and without SADa,b
MDD with SAD MDD without SAD
Spring 7 (19.4%) 53 (24.7%)
Summer 3 (8.3%) 39 (18.1%)
Autumn 10 (27.8%) 67 (31.2%)
Winter 16 (44.4%) 56 (26.0%)
Total 36 (100%) 215 (100%)
MDD, current major depressive disorder; SAD, seasonal affective disorder. a. In 
order to enhance the contrast between the groups, 32 participants with MDD and 
sub-SAD were excluded from this analysis. b. Chi-square test: P=0.118.
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In conclusion, our study suggests that, within a clinical popu-
lation, SAD is a measure of severity with high levels of symptoms 
throughout the year and a perceived worsening of symptoms in the 
winter months. However, more research is needed, especially long-
term follow-up studies with regular measurements within the dif-
ferent seasons, including physiological correlates, of patients who 
are diagnosed with SAD according to DSM-5 criteria.
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